Valuation : ARS Pharmaceuticals, Inc.

Market Cap 503M 434M 411M 372M 698M 48.08B 702M 4.87B 1.87B 24.43B 1.89B 1.85B 77.27B P/E 2026 *
-2.57x
P/E 2027 * -5.63x
Enterprise Value 503M 434M 411M 372M 698M 48.08B 702M 4.87B 1.87B 24.43B 1.89B 1.85B 77.27B EV / Sales 2026 *
3.87x
EV / Sales 2027 * 2.64x
Free-Float
83.82%
Yield 2026 *
-
Yield 2027 * -
1 day+1.26%
1 week-16.05%
Current month-20.67%
1 month-19.46%
3 months-48.60%
6 months-46.28%
Current year-59.14%
1 week 4.73
Extreme 4.73
5.54
1 month 4.73
Extreme 4.73
6.58
Current year 4.73
Extreme 4.73
13.15
1 year 4.73
Extreme 4.73
13.15
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 05/08/2015
Chief Executive Officer 53 07/07/2026
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap. Importance
1/9/26 Free

Executive/Senior Manager

1,001,738 1.0073%
1/7/26 Free

Chief Executive Officer

898,456 0.9048%
24/6/26 Free

Director

30,000 0.0302%
Change 5-day change 1-year change 3-year change Capi.($)
-5.93%-16.05%-54.67%-35.41% 503M
-0.71%-8.73%-4.56%+9.80% 46.05B
+0.21%-3.37%+403.76%+534.40% 43.59B
+1.74%-3.63%+42.37%+22.59% 42.35B
+1.38%-4.46%+10.38%+79.88% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+0.87%-2.81% - - 17.16B
+0.75%-0.99%+23.25%+116.71% 16.28B
-0.31%-3.76%+12.33%+30.49% 14.32B
+1.93%-5.14%+81.55%+39.31% 13.03B
Average +0.57%-5.36%+58.30%+92.92% 26.44B
Weighted average by Cap. +0.40%-5.11%+86.99%+128.94%

Financials

2026 *2027 *
Net sales 130M 112M 106M 96.04M 180M 12.41B 181M 1.26B 484M 6.31B 488M 477M 19.95B 191M 164M 156M 141M 264M 18.21B 266M 1.85B 710M 9.26B 716M 700M 29.27B
Net income -184M -159M -150M -136M -255M -17.58B -257M -1.78B -686M -8.94B -691M -676M -28.26B -85.02M -73.32M -69.38M -62.85M -118M -8.12B -119M -823M -317M -4.13B -319M -312M -13.05B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
198
Date Price Change Volume
11/09/26 USD 4.760 -5.93% 2,570,229
10/09/26 USD 5.060 -3.25% 1,091,279
09/09/26 USD 5.230 -2.97% 874,545
08/09/26 USD 5.390 -4.09% 1,086,519
04/09/26 USD 5.620 -0.88% 852,847
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.760USD
Average target price
22.50USD
Spread / Average Target
+372.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRY Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!